Immuneering (IMRX) Profit After Tax (2020 - 2026)
Immuneering (IMRX) posted quarterly Profit After Tax of -$13.8 million for Q1 2026, up 8.39% year-over-year from -$12.7 million in Q1 2025, and down 19.87% quarter-over-quarter from -$11.5 million in Q4 2025.
Immuneering (IMRX) Profit After Tax (2020 - 2026) Analysis & Trends
Immuneering's Profit After Tax history runs 7 years deep, the most recent figure standing at -$13.8 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 8.39% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$54.7 million (up 11.48% YoY), while the FY2025 annual figure was -$55.9 million, up 8.34% from the prior year.
- Profit After Tax for Q1 2026 stood at -$13.8 million, down from -$11.5 million in the prior quarter.
- The five-year high for Profit After Tax was $38.4 million in Q4 2023, with the low at -$18.1 million in Q4 2024.
- The 5-year median for Profit After Tax is -$12.9 million (2022), against an average of -$6.2 million.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax surged 445.9% in 2022, then slumped 85942.27% in 2023.
- Immuneering's Profit After Tax stood at $37.3 million in 2022, then climbed by 2.94% to $38.4 million in 2023, then plunged by 147.03% to -$18.1 million in 2024, then jumped by 36.3% to -$11.5 million in 2025, then dropped by 19.87% to -$13.8 million in 2026.
- Business Quant data shows IMRX's Profit After Tax at -$13.8 million in Q1 2026, -$11.5 million in Q4 2025, and -$15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -17.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.44 Mn |
| Mar 31, 2026 | -13.78 Mn |
| Dec 31, 2025 | -11.50 Mn |
| Sep 30, 2025 | -14.96 Mn |
| Jun 30, 2025 | -14.43 Mn |
| Mar 31, 2025 | -15.05 Mn |
| Dec 31, 2024 | -18.05 Mn |
| Sep 30, 2024 | -14.60 Mn |
| Jun 30, 2024 | -14.08 Mn |
| Mar 31, 2024 | -14.31 Mn |
| Dec 31, 2023 | 38.38 Mn |
| Sep 30, 2023 | -12.60 Mn |
| Jun 30, 2023 | -12.19 Mn |
| Mar 31, 2023 | 30,626.00 |
| Dec 31, 2022 | 37.29 Mn |
| Sep 30, 2022 | -12.84 Mn |
| Jun 30, 2022 | -14,166.00 |
| Mar 31, 2022 | -12.90 Mn |
| Dec 31, 2021 | -10.78 Mn |
| Sep 30, 2021 | -8.54 Mn |